Amylyx Pharmaceuticals Long Term Debt

As of the most recent data (June 2026), AMLX shows a long-term debt of $4.2M. That compares with $11M in the prior-year period — down 59.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMLX's long-term debt is now $4.2M (was $11M) — a 59.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Amylyx Pharmaceuticals is outperforming or lagging.

Tracking AMLX's long-term debt over time shows whether Amylyx Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $4.2M That compares with $11M in the prior-year period — down 59.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Amylyx Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $4.2M) with ownership activity and broader fundamentals.